Medical Costs of Respiratory Syncytial Virus–Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019-Reference-Cited by-同舟云学术

Medical Costs of Respiratory Syncytial Virus–Associated Hospitalizations and Emergency Department Visits in Children Aged Younger Than 5 Years: Observational Findings from the New Vaccine Surveillance Network, 2016-2019

Published:2024-08 Issue: Volume:271 Page:114045
ISSN:0022-3476
Container-title:The Journal of Pediatrics
language:en
Short-container-title:The Journal of Pediatrics

Author:

Clopper Benjamin R.^ORCID,Zhou Yingtao,Tannis Ayzsa,Staat Mary Allen,Rice Marilyn,Boom Julie A.,Sahni Leila C.,Selvarangan Rangaraj,Harrison Christopher J.,Halasa Natasha B.,Stewart Laura S.,Weinberg Geoffrey A.,Szilagyi Peter G.,Klein Eileen J.,Englund Janet A.,Rha Brian,Lively Joana Y.,Ortega-Sanchez Ismael R.,McMorrow Meredith L.,Moline Heidi L.

Funder

Centers for Disease Control and Prevention

Publisher

Elsevier BV

Reference25 articles.

1. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age;Hall;Pediatrics,2013

2. Trends in respiratory syncytial virus and bronchiolitis hospitalization rates in high-risk infants in a United States nationally representative database, 1997-2012;Doucette;PLoS One,2016

3. Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States, 2014-15;Arriola;J Pediatric Infect Dis Soc,2020

4. Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis;McLaughlin;J Infect Dis,2022

5. A systematic literature review of the burden of respiratory syncytial virus and health care utilization among United States infants younger than 1 year;Suh;J Infect Dis,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Women's acceptance of two strategies for preventing respiratory syncytial virus infant bronchiolitis: maternal immunization or monoclonal antibodies for newborns;Clinical Microbiology and Infection;2024-07

2. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season;Vaccines;2024-05-17